key: cord-0963144-yc613g96
authors: Hakeem, Abdul Rahman; Padmanaban, Hrishikesh; Karthikeyan, Srinath; Murugesan, Sivakumar; Menon, Jagadeesh; Shanmugam, Naresh; Jothimani, Dinesh; Reddy, Mettu Srinivas; Rela, Mohamed
title: Awareness and concerns among adult Liver Transplant recipients in the current pandemic caused by novel coronavirus (COVID-19): Strategies to safeguard a high-risk population
date: 2020-06-11
journal: J Clin Exp Hepatol
DOI: 10.1016/j.jceh.2020.06.001
sha: 4bd9f25bd720d422bf5a3c3b1f7334b98c39b67f
doc_id: 963144
cord_uid: yc613g96

BACKGROUND: The coronavirus disease 2019 (COVID-19) virus is spreading rapidly and there are obvious concerns for the immunocompromised patient population including transplant recipients. Creating awareness and understanding patient concerns will play an important role in protecting this vulnerable group in developing timely and appropriate healthcare interventions. METHODS: A cross-sectional online survey was conducted between 23(rd) March 2020 & 1(st) April 2020 among 154 liver transplant recipients, transplanted between October 2018 and February 2020. An 18-point questionnaire explored their knowledge of COVID-19, awareness of recipient’s high-risk status, interventions to minimize cross-infections and concerns of this patient group regarding the pandemic. RESULTS: There were 112 (73%) respondents, with median age of 53 years (81% males). There was no difference in demographics between those who responded (n=112), to those who did not respond to the survey (n=42). Most of the recipients were aware of the main symptoms of COVID-19, such as fever (92%), breathlessness (86%), dry cough (87%), but less than half were aware of diarrhea (39%) as a symptom. Awareness about spread from asymptomatic individuals was limited (26%). Majority (95%) understood their high-risk status, but worryingly 23% of the respondents felt that there was no risk in visiting the hospital for routine clinic visit and blood tests. Concerns were raised by the recipients mostly regarding the uncertainties of COVID-19 infection and its treatment options, the quality of information on social messaging platforms and lack of access to routine tests/immunosuppression levels due to lockdown/social distancing. CONCLUSIONS: Our liver transplant recipients have a reasonable awareness regarding COVID-19. Problems in accessing the healthcare system during prolonged periods of lockdown was a major concern. It is important for each transplant unit to educate, support and remain accessible to this vulnerable patient cohort as the pandemic continues to progress worldwide.

Background:

The coronavirus disease 2019 (COVID-19) virus is spreading rapidly and there are obvious concerns for the immunocompromised patient population including transplant recipients. Creating awareness and understanding patient concerns will play an important role in protecting this vulnerable group in developing timely and appropriate healthcare interventions.

A cross-sectional online survey was conducted between 23 rd March 2020 & 1 st April 2020 among 154 liver transplant recipients, transplanted between October 2018 and February 2020. An 18-point questionnaire explored their knowledge of COVID-19, awareness of recipient's high-risk status, interventions to minimize cross-infections and concerns of this patient group regarding the pandemic.

There were 112 (73%) respondents, with median age of 53 years (81% males). There was no difference in demographics between those who responded (n=112), to those who did not respond to the survey (n=42). Most of the recipients were aware of the main symptoms of COVID-19, such as fever (92%), breathlessness (86%), dry cough (87%), but less than half were aware of diarrhea (39%) as a symptom. Awareness about spread from asymptomatic individuals was limited (26%). Majority (95%) understood their high-risk status, but worryingly 23% of the respondents felt that there was no risk in visiting the hospital for routine clinic visit and blood tests.

Concerns were raised by the recipients mostly regarding the uncertainties of COVID-19 infection and its treatment options, the quality of information on social messaging platforms and lack of access to routine tests/immunosuppression levels due to lockdown/social distancing.

Our liver transplant recipients have a reasonable awareness regarding COVID-19. Problems in accessing the healthcare system during prolonged periods of lockdown was a major concern. It is important for each transplant unit to educate, support and remain accessible to this vulnerable patient cohort as the pandemic continues to progress worldwide.

Coronavirus disease (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has spread to 215 countries and affected over 4.5 million individuals with 308,676 reported dead, as of May 16, 2020 (1) . There is growing concern for the high-risk populations, especially the elderly and the immunocompromised (2) . The immune response of transplant recipients, particularly the T-cell immune response, is significantly suppressed due to long-term use of immunosuppressive agents (3) . Clinical manifestations of COVID-19 in this cohort may hence be atypical and potentially more severe when compared to the non-transplant patients (4).

Data on liver transplant recipients infected with SARS-CoV-2 is still limited to case reports and small series (4) (5) (6) (7) (8) . The first reported COVID-19 infection in a liver transplant patient was from Wuhan, in a 37-year old recipient, who developed severe COVID infection in the post-transplant period and was subsequently discharged after two months of hospitalization (6) . Lombardy, one of the most affected regions in Italy, reported three of their 111 long-term liver transplant patients died due to COVID-19, all of them transplanted more than 10 years ago and they were more than 65 years old (9) . However, reports from the multiple centres from US have shown that the infection in transplant patients is much severe, with higher mortality and affects much younger recipient population, compared to non-transplant population (7, 8) .

Social distancing and personal-hygiene seem to be the two main factors with the potential to prevent the spread of the virus (10). Following a temporary lockdown period lasting 14 hours on the 22 nd of March 2020, the Indian Government extended the lockdown period to 21 days to prevent community spread of this highly infectious virus. For the transplant population on lifelong immunosuppression and accustomed to frequent clinic visits and routine blood tests, this is uncharted territory! There is hence an urgent need for focused education of this patient cohort. We conducted an online survey to identify potential gaps in knowledge amongst the recipient population and their major concerns regarding the pandemic.

This study was conducted as a cross-sectional online survey using a commercially available online survey software (www.surveymonkey.com). India's first case of COVID-19 case was reported on 30 th January. The largest COVID-19 national lockdown in the World started on 25 th March for 21 days until 14 th April, which was subsequently extended to 3 rd May. The survey was initiated following the 14-hour curfew on the 23 rd March and completed on the 1 st of April. All recipients received an initial telephone call to explain the completely voluntary nature of the survey and asking them if they were interested to participate. The survey was then sent to them through WhatsApp messaging. Those who didn't respond by 29 th March were given a single reminder call. The recipients were asked to fill the questionnaire independent of any help from others. Survey by telephone was avoided, due to the risk of adding unnecessary bias by the call from the transplant unit. information (4 questions), high-risk status assessment (7 questions) and concerns (4 questions). Opportunity was also provided for conveying any additional concerns in a free-text format (survey questionnaire available as supplemental file).

Descriptive methods of data presentation were used. Categorical variables are expressed as frequencies and proportions (%) and continuous variables are presented as median (range). Approval for this study was obtained from the institutional review board.

The flowchart depicts the study inclusions and exclusions ( Figure 1 ). Following exclusions, we were left with 154 (41.3%) adult liver transplant recipients (123 LDLT and 31 DDLT) of Indian origin, of which 112 (73%) responded to the survey. The median age of the respondents was 53 years (range 18-64 years), 81% were male and majority were living donor recipients (79% LDLT versus 21% DDLT). 9% were transplanted in 2020, 63% in 2019 and 28% in 2018. Median time since transplant was 8.6 months. There was no difference in demographic characteristics with the cohort which did not respond to the survey (n=42; 27%), which minimizes the risk of non-response bias ( Table 1) .

Majority of the recipients were aware of the common symptoms of COVID-19, s as fever (92%), breathlessness (86%), dry cough (87%), but less than half were aware of diarrhea (39%) as one of the main symptoms. It is worrying that only 26% of the recipients felt that the COVID-19 infection can be spread by asymptomatic patients similar to those with symptoms while 16% felt that asymptomatic individuals were no risk to the community. Majority of the recipients were aware of the droplet spread by coughing/sneezing (89%), spread through surfaces (77%), spread through touching infected person/secretions (78%). But only 18% were aware of the oral/faeco-oral route as one of the modes of transmission. 94% of the recipients understood the importance of social distancing and felt this as the best means of preventing COVID-19 infection ( Table 2) .

Majority of the recipients felt that coronavirus infection can affect transplant patients more than the normal population (Strongly agree 74% and Agree 21%) and the non-transplant patients (Strongly agree 65% and Agree 30%). In compliance with current social distancing guidelines and the Government of India lockdown restrictions, 71% of the recipients stayed at home and a fifth (20%) minimized contact with other family members and visitors. Only a small percentage ventured out of the home with mask (6%) and a minority (3%) did not follow any additional restrictions. 82% of the respondents were clear that they would contact their doctor or the transplant unit for advice, if they or their family members develop symptoms of flu such as fever, cough or running nose. It is reassuring that 96% will not stop or modify immunosuppression and would rather consult their transplant unit for advice, for any flu-like illness ( Table 2) .

Majority of the recipients (70%) understood the risk of acquiring the infection during travel to the hospital for routine appointments and blood tests and would rather contact the transplant unit by telephone for advice. It is worrying that 23% of the respondents felt that there is no risk and they would be happy to visit hospital for routine tests. 96% of the respondents liked the idea of video consultation during this period of social distancing and lockdown (Table 2) .

3% of respondents have had self-limiting respiratory illness in the last 4 weeks, which had caused them some concern to them in the background of the coronavirus outbreak. 75% of the respondents felt that the Indian Government should offer testing to transplant patients for any flu-like symptoms in view of their high-risk status even in the absence of other high-risk criteria such as international travel (Figure 2 ). Majority of them obtained their COVID-19 news from television (81%), WhatsApp (39%) and newspaper (38%) though a third (29%) had already contacted their doctor for information on COVID-19. Patients reported wrong information received on social media platforms, difficult access to healthcare and disruption of their supply of immunosuppressive medications due to the prolonged lockdown as major concerns (see Table 3 ).

Severe infections in transplant recipients has been previously reported with Severe Acute Respiratory Syndrome (SARS-CoV) and Middle East Respiratory Syndrome (MERS-CoV) viruses (11, 12) . Respiratory virus infection in transplant recipients can cause more than just a cold, with reports of prolonged illness, extended viral shedding, progression to severe disease with resultant higher morbidity and mortality (13) . Because of their immunosuppressed state, these patients may also present with atypical symptoms (14) .

Our survey has demonstrated that liver transplant recipients have reasonable knowledge about the COVID-19 pandemic and most are aware of their high-risk status. However, they are concerned about the current situation and to an extent, confused by the information available on various social platforms. Their concern with the current situation was apparent with 285 questions being asked by 85 recipients, an average of 3.4 questions per person. It is heartening that most recipients reported their intention to contact the transplant unit for any advice when faced with doubts regarding their graft. Data from this survey has informed us during the preparation of a detailed information leaflet regarding COVID-19 for our recipients. We have also started video consultations to minimize the need for hospital visits and increased home visits by phlebotomists for collecting blood samples.

Reliable access to immunosuppressive medications during the period of lockdown was also identified as a major concern and we are undertaking measures to ensure home delivery of medications for these recipients.

For those who are not infected with COVID-19 or are asymptomatic, we did not advise any change in immunosuppression and the immunosuppressant dosage levels were titrated as per the trough levels. We also did not alter the frequency of our follow-up from our routine post-transplant protocol, but ensured patients were reviewed in the virtual clinics. For those patients who do need a face to face clinic review, for example to check their wounds or to get an ultrasound scan, we ensured their visit was planned in advance and their stay in hospital is short, adhering to all social distancing measures. Based on the guidance available, we do not advise COVID-19 testing for asymptomatic recipients (15) .

Transplantation involves a lifelong contract between the patient and the transplant team. Confidence in the healthcare system is essential so that in extreme situations such as this, the patient knows that the most reliable advice is easily available from the transplant team. We believe that questionnaires such as these not only help us in understanding the immediate and urgent concerns of our patients but only periodically remind patients about our commitment to their well-being. Most of the interventions which we have undertaken have also been suggested in the recently published AASLD guidelines (13) . A survey done on 640 liver transplant recipients in Milan, Italy, showed that 81% of them adhered to at least two COVID-19 preventive measures (frequent handwashing, sanitization, avoiding crowded places and wearing masks), with only 8 recipients (1.25%) diagnosed with nCoV infection. This survey elucidated the importance of preventive measures in this high-risk population, which eventually led this group to move to telemedicine to deliver care to liver transplant recipients (16) .

The major strength of this survey is its generalizability to all transplant patients. Given the rapid pace at which the COVID-19 pandemic is progressing and the uncertainty regarding its future course, it is vitally important that the transplant community is prepared to prevent dangerous consequences in a vulnerable patient group.

Although there might be minor variations based on local practice across centers Worldwide, our study has underscored the need to interact with recipients and respond to their needs. Measures to minimize non-essential hospital visits for the recipient, maintain open channels of communication with the treating team and ensuring an uninterrupted supply of immunosuppressive medications during periods of lockdowns are key issues to address during these uncertain times. 

No, I don't feel there is a risk and routine tests can be done There is a definite risk and I want to defer the labs There is a risk, so will contact the transplant centre for advice 26 "Is COVID-19 airborne?" "How dangerous is this virus?" "How long it will stay in our body?" "Newspaper touching should be avoided?" "If COVID-19 affect any transplant patients will any treatment be effective to cure it?" "If a transplant recipient gets infected by COVID-19, what is the prognosis?" "When the vaccine will be available for covid-19?" "How far can COVID-19 transmit in the mode of air how much distance should we maintain. Is staying at home for the next 15 days sufficient? Or is it necessary to isolate oneself at home from other family members?"

"Can I use air conditioner in night, some of the information I came to know is to avoid cold things and AC is that true?" "Can I have egg and chicken as there is news about bird flu?" "Why so much fear created by Government?" "Sunlight will destroy the virus?" "What is special diet chart to prevent Corona for us?"

"Any major precautions I have to take?" "Can I take Tablet. Plaquenil and Tablet. Hydroxychloroquine" "I need to go to shop for business but I am using sanitizer and wearing mask (N95) , is that fine?" "What should I do with the immunosuppressant medications if I have flu like symptoms?" "Should we wear masks even when we are at home?"

"How to procure immunosuppressive and other medicines in case of the courier services being stopped?" "My check-up is due now. How long should I wait for next check-up?" "How can take liver function tests and tacrolimus level tests?" "Where to get blood tests as no transport available?" "Can centre help to get important medicine for transplant patients if they are facing shortage of meds?" "For how many days tentatively we should stock up the medicines for?" "In a lockdown situation with limited food resources what should my diet be?"

"Should I inform my situation with the local health authorities?" "Does the donor has to follow the same instructions given for recipient?" "Can I use alcohol based sanitizer?" "What should I do if there is an emergency?" Copyright assignment: In consideration of the Indian National Association for the Study of the Liver ("INASL") taking action to review and edit my submission, including possible re-design of figures and tables, and any other supplemental tables, illustration or other information submitted, herewith ("Article"), the undersigned Author, hereby transfers, conveys, and assigns all rights, titles and interests therein, including any and all copyrights to the INASL, however the Author will be always mentioned as such. As an exception to this rule, the Author acknowledges that the INASL will appear as the author when she/he participates in writing the Clinical Practice Guidelines. The Author will in this context be mentioned in a footnote as being a contributor. By signing this form I agree to INASL using any illustration (images or parts thereof) from the Article on the cover of the Journal of Clinical and Experimental Hepatology, on the INASL and Journal websites, and in any marketing material. In addition to reproduction in conventional printed and electronic (including online systems) forms, in all media (whether known or developed hereinafter), worldwide, in all languages, the Article will be stored electronically and the archived articles will be made available in electronic services. Assignment of copyright signifies agreement to the INASL making arrangements to include the Article in bundling of articles, document delivery services, CD-ROMS and electronic databases, etc. worldwide. In the light of the above, I acknowledge that to the extent permitted by applicable law any exploitation or other use (including translations, reprints, etc.) of the Article or of parts of it, either by myself or by a third party, is subject to the INASL's prior written consent. Should the INASL not publish the Article, the INASL agrees to release its rights therein.

Authorship Responsibility: I, the undersigned Author, on behalf of all other Authors, certify that all Authors have participated sufficiently in the intellectual content, the analysis of data, if applicable, and the writing of the Article, and production of illustrations, to take public responsibility for it. I further certify that the Article contains no libellous or other unlawful statements and does not contain any materials that violate any personal or proprietary rights of any third party. I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in my Article. I have reviewed the final version of the Article, believe it represents valid work, and approve it for publication.

As an Author of this Article, I certify that none of the material in the Article has been published previously, is included in another manuscript or is currently under consideration for publication elsewhere. I also certify that this Article has not been accepted for publication elsewhere, nor have I assigned any right or interest in the manuscript to any third party (including employers, principals or governmental bodies). Moreover, should the INASL request data, upon which the Article is based, I shall produce it. a) The Authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript b) The Authors who have taken part in this study do not have a relationship with the manufacturers of the drugs involved either in the past or present and did not receive funding from the manufacturers to carry out their research. The Authors received support from …..

c) The Authors who have taken part in this study have declared a relationship with the manufacturers of the drugs involved.

d) The Authors have declared that they received funding from the drug companies involved in order to carry out their research in this manuscript.

e) The Authors who have taken part in this study have declared a relationship with the manufacturers of the device/materials involved.

f) The Authors have declared that they received funding from the manufacturers of the device/materials involved in order to carry out their research in this manuscript.

g) The underlying research reported in the study was funded by the NIH Institutes of Health I, the undersigned, on behalf of all Authors, certify that that the above statement is true. Author Permission to re-design graphics I, the undersigned Author, on behalf of all other Authors, give the Journal of Clinical and Experimental Hepatology the permission to re-design figures and tables in order to suit its presentation style. The scientific content and meaning will not be modified, and the re-designed figures will be approved by the authors before the galley proofs.

Signed:

Date: 29/04/2020

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Viral infections in solid organ transplant recipients: novel updates and a review of the classics

Fatal outcome in a liver transplant recipient with COVID-19

Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient

Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient

Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States

COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter

COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening

Rare and emerging viral infections in transplant recipients

Respiratory viruses in transplant recipients: more than just a cold. Clinical syndromes and infection prevention principles

Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement

Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?

Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI)

Health status of liver transplanted patients during the coronavirus outbreak in italy: a large single center experience from Milan